力生制药：2025年半年度净利润约3.43亿元，同比增加235.04%

Core Viewpoint - Lisheng Pharmaceutical reported a mixed performance in its semi-annual earnings, with a decline in revenue but a significant increase in net profit and earnings per share [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 732 million yuan, representing a year-on-year decrease of 1.76% [2] - The net profit attributable to shareholders was around 343 million yuan, showing a substantial year-on-year increase of 235.04% [2] - Basic earnings per share reached 1.33 yuan, which is an increase of 232.5% compared to the previous year [2]